EUVIMEDEUVIMED entdecken
Crossref

Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg)

Therapieforum Transplant · 01.06.2018 · 06 (01) · 4-13

DOI: 10.1055/a-0667-7056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapieforum Transplant, erschienen am 01.06.2018.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The preservation of donor organs through machine perfusion (MP) creates new opportunities in transplantation medicine for the benefit of patients. In view of the organ shortage and the increasing number of marginal organs, there is a need to establish MP in Germany in order to improve organ utilization and therapeutic outcomes. In kidney transplantation, the use of MP can significantly improve 1-year survival. MP also offers advantages in liver, heart, and lung transplantation. As recommended by the Organ Donation Committee (KfO, Kommission für Organspende) of the German Transplantation Society (DTG, Deutsche Transplantationsgesellschaft) as well as the Permanent Committee on Organ Transplantation (StäKO, Ständige Kommission Organtransplantation), its use should be initially adopted in standard care in the form of hypothermic machine perfusion in kidney transplantation and then be further extended.

Zitieren

APA

(2018). Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg). Therapieforum Transplant, 06(01), 4-13. https://doi.org/10.1055/a-0667-7056

Vancouver

Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg). Therapieforum Transplant. 2018;06(01):4-13. doi:10.1055/a-0667-7056

BibTeX
@article{euvimed2018,
  title = {Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg)},
  journal = {Therapieforum Transplant},
  year = {2018},
  volume = {06},
  number = {01},
  pages = {4--13},
  doi = {10.1055/a-0667-7056}
}
Kostenlos starten →